PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Debenture Offering

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has completed the sale of 1,240 units, with each unit consisting of one 4% senior secured $1,064 ‎principal amount convertible debenture and 16,369 share purchase warrants. The sale, which was resulted in gross proceeds of $1,240,000 for the company, was completed on July 27, 2022. According to the announcement, the principal amount and accrued but unpaid interest on each debenture is ‎convertible into common shares of the company; that conversion is done at the option of the holder at any ‎time following the closing date at a price of ‎$0.065 per common share‎. The company noted that the debentures will mature 24 months from the closing date and will bear interest at a rate of 4% ‎per annum, payable quarterly on the last business day of each calendar quarter. The announcement also noted that all outstanding principal amounts along with all unpaid ‎interest must be repaid at the maturity date. The company also observed that all securities issued in the debenture offering are subject to a hold period of four ‎‎months and one day from the closing date. ‎Delic intends to use the proceeds from the debenture for expansion and general corporate purposes.

To view the full press release, visit https://ibn.fm/YvjTd

About Delic Holdings

Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including Ketamine Wellness Centers, the largest chain of psychedelic wellness clinics in the country; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premier psychedelic wellness event; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products and effective treatment options to the masses. For more information about the company, visit www.DelicCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Jill Conwell as Chief People Officer

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising.…

10 hours ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Subsidiary HOPE Therapeutics Opens Palm Beach Clinic for Depression and PTSD Treatment

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its subsidiary HOPE Therapeutics has opened a new clinic…

3 days ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has appointed Prof. Joshua C. Brown, MD,…

1 week ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway 

NRx Pharmaceuticals (NASDAQ: NRXP) announced completion of an in-person Type C guidance meeting with the U.S.…

3 weeks ago

PsychedelicNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Positive Phase 2a SPL026 Data Published in Nature Medicine

This NewsBreak has been disseminated on behalf of Helus Pharma and may include paid advertising.…

3 weeks ago

PsychedelicNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has licensed regulatory-grade real-world evidence drawn from more than…

2 months ago